Visual function in patients with choroidal neovascularization resulting from age-related macular degeneration: The importance of looking beyond visual acuity

Optometry and Vision Science

Volumn 83, Issue 3, 2006, Pages 178-189

  Fletcher, Donald C ^a,c   Schuchard, Ronald A ^b  

^a SMITH KETTLEWELL EYE RESEARCH INSTITUTE   (United States)

^b Atlanta VA Rehab R and D Center   (United States)

^c CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

Author keywords

Age related macular degeneration; Choroidal neovascularization; Contrast sensitivity; Laser photocoagulation; Pegaptanib sodium; Scotoma; Verteporfin therapy; Visual acuity; Visual field

Indexed keywords

HEALTH CARE; LASERS; MEDICINE; VISION; VISION AIDS;

AGE-RELATED MACULAR DEGENERATION; CHOROIDAL NEOVASCULARIZATION; CONTRAST SENSITIVITY; LASER PHOTOCOAGULATION; PEGAPTANIB SODIUM; SCOTOMA; VISUAL ACUITY; VISUAL FIELD;

PATIENT MONITORING;

BENZOPORPHYRIN DERIVATIVE; PEGAPTANIB;

AGE DISTRIBUTION; APTITUDE; CLINICAL TRIAL; CONTRAST SENSITIVITY; DAILY LIFE ACTIVITY; DRIVING ABILITY; DRUG EFFECT; ENDOPHTHALMITIS; EYE DISEASE; HEALTH CARE NEED; HEALTH PROGRAM; HUMAN; INJURY; LASER COAGULATION; LENS DISEASE; MEDICAL LITERATURE; MEDICAL SPECIALIST; MEDLINE; OPHTHALMOLOGY; OPTOMETRY; PATHOGENESIS; PATIENT CARE; PHOTODYNAMIC THERAPY; PHYSICIAN; PREDICTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY CONTROL; READING; RETINA DETACHMENT; RETINA MACULA DEGENERATION; REVIEW; RISK FACTOR; RISK REDUCTION; SCOTOMA; SUBRETINAL NEOVASCULARIZATION; SYSTEMIC DISEASE; TASK PERFORMANCE; VISION; VISUAL ACUITY; VISUAL ADAPTATION; VISUAL FIELD; VISUAL IMPAIRMENT;

CHOROIDAL NEOVASCULARIZATION; CONTRAST SENSITIVITY; DISEASE PROGRESSION; HUMANS; MACULAR DEGENERATION; PROGNOSIS; VISUAL ACUITY; VISUAL FIELDS;

EID: 33645105718     PISSN: 10405488     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.opx.0000204510.08026.7f     Document Type: Review

References (100)

1. Foran S, Wang JJ, Mitchell P. Causes of visual impairment in two older population cross-sections: the Blue Mountains Eye Study. Ophthalmic Epidemiol 2003;10:215-25.
2. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS Report No. 8. Arch Ophthalmol 2001;119:1417-36.
3. Verteporfin Roundtable Participants. Guidelines for using verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: update. Retina 2005;25:119-34.
4. Kniestedt C, Stamper RL. Visual acuity and its measurement. Ophthalmol Clin North Am 2003;16:155-70.
5. Rosser DA, Laidlaw DA, Murdoch IE. The development of a "reduced logMAR" visual acuity chart for use in routine clinical practice. Br J Ophthalmol 2001;85:432-6.
6. Laidlaw DA, Abbott A, Rosser DA. Development of a clinically feasible logMAR alternative to the Snellen chart: performance of the "compact reduced logMAR" visual acuity chart in amblyopic children. Br J Ophthalmol 2003;87:1232-4.
7. Bellmann C, Unnebrink K, Rubin GS, Miller D, Holz FG. Visual acuity and contrast sensitivity in patients with neovascular age-related macular degeneration. Results from the Radiation Therapy for Age-Related Macular Degeneration (RAD-) Study. Graefes Arch Clin Exp Ophthalmol 2003;241:968-74.
8. Bressler SB, Bressler NM, Fine SL, Hillis A, Murphy RP, Olk RJ, Patz A. Natural course of choroidal neovascular membranes within the foveal avascular zone in senile macular degeneration. Am J Ophthalmol 1982;93:157-63.
9. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials - TAP Report 1. Arch Ophthalmol 1999;117:1329-45.
10. Rubin GS, Roche KB, Prasada-Rao P, Fried LP. Visual impairment and disability in older adults. Optom Vis Sci 1994;71:750-60.
11. Wood JM. Age and visual impairment decrease driving performance as measured on a closed-road circuit. Hum Factors 2002;44:482-94.
12. Klein BE, Moss SE, Klein R, Lee KE, Cruickshanks KJ. Associations of visual function with physical outcomes and limitations 5 years later in an older population: the Beaver Dam eye study. Ophthalmology 2003;110:644-50.
13. Dargent-Molina P, Favier F, Grandjean H, Baudoin C, Schott AM, Hausherr E, Meunier PJ, Breart G. Fall-related factors and risk of hip fracture: the EPIDOS prospective study. Lancet 1996;348:145-9.
14. Ivers RQ, Cumming RG, Mitchell P, Attebo K. Visual impairment and falls in older adults: the Blue Mountains Eye Study. J Am Geriatr Soc 1998;46:58-64.
15. Klein BE, Klein R, Lee KE, Cruickshanks KJ. Performance-based and self-assessed measures of visual function as related to history of falls, hip fractures, and measured gait time. The Beaver Dam Eye Study. Ophthalmology 1998;105:160-4.
16. Williams RA, Brody BL, Thomas RG, Kaplan RM, Brown SI. The psychosocial impact of macular degeneration. Arch Ophthalmol 1998;116:514-20.
17. Brown GC, Sharma S, Brown MM, Kistler J. Utility values and age-related macular degeneration. Arch Ophthalmol 2000;118:47-51.
18. Rubin GS, Bandeen-Roche K, Huang GH, Munoz B, Schein OD, Fried LP, West SK. The association of multiple visual impairments with self-reported visual disability: SEE project. Invest Ophthalmol Vis Sci 2001;42:64-72.
19. Brown GC, Brown MM, Sharma S. Difference between ophthalmologists' and patients' perceptions of quality of life associated with age-related macular degeneration. Can J Ophthalmol 2000;35:127-33.
20. Pelli DG, Robson JG, Wilkins AJ. The design of a new letter chart for measuring contrast sensitivity. Clin Vision Sci 1988;2:187-99.
21. Rubin GS. Reliability and sensitivity of clinical contrast sensitivity tests. Clin Vision Sci 1988;2:169-77.
22. Mones J, Rubin GS. Contrast sensitivity as an outcome measure in patients with subfoveal choroidal neovascularisation due to age-related macular degeneration. Eye 2005;19:1142-50.
23. Crossland MD, Culham LE, Rubin GS. Predicting reading fluency in patients with macular disease. Optom Vis Sci 2005;82:11-7.
24. Rubin GS, West SK, Munoz B, Bandeen-Roche K, Zeger S, Schein O, Fried LP. A comprehensive assessment of visual impairment in a population of older Americans. The SEE Study. Salisbury Eye Evaluation Project. Invest Ophthalmol Vis Sci 1997;38:557-68.
25. Rabin J. Luminance effects on visual acuity and small letter contrast sensitivity. Optom Vis Sci 1994;71:685-8.
26. Mustonen J, Rovamo J, Nasanen R. The effects of grating area and spatial frequency on contrast sensitivity as a function of light level. Vision Res 1993;33:2065-72.
27. Rubin GS, Bressler NM. Effects of verteporfin therapy on contrast on sensitivity: results from the Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Investigation - TAP report No 4. Retina 2002;22:536-44.
28. Scott IU, Feuer WJ, Jacko JA. Impact of visual function on computer task accuracy and reaction time in a cohort of patients with age-related macular degeneration. Am J Ophthalmol 2002;133:350-7.
29. Hassan SE, Lovie-Kitchin JE, Woods RL. Vision and mobility performance of subjects with age-related macular degeneration. Optom Vis Sci 2002;79:697-707.
30. Kuyk T, Elliott JL. Visual factors and mobility in persons with age-related macular degeneration. J Rehabil Res Dev 1999;36:303-12.
31. Marron JA, Bailey IL. Visual factors and orientation-mobility performance. Am J Optom Physiol Opt 1982;59:413-26.
32. Varano M, Scassa C. Scanning laser ophthalmoscope microperimetry. Semin Ophthalmol 1998;13:203-9.
33. Sunness JS, Schuchard RA, Shen N, Rubin GS, Dagnelie G, Haselwood DM. Landmark-driven fundus perimetry using the scanning laser ophthalmoscope. Invest Ophthalmol Vis Sci 1995;36:1863-74.
34. Fletcher DC, Schuchard RA. Preferred retinal loci relationship to macular scotomas in a low-vision population. Ophthalmology 1997;104:632-8.
35. Sunness JS, Applegate CA, Haselwood D, Rubin GS. Fixation patterns and reading rates in eyes with central scotomas from advanced atrophic age-related macular degeneration and Stargardt disease. Ophthalmology 1996;103:1458-66.
36. Lei H, Schuchard RA. Using two preferred retinal loci for different lighting conditions in patients with central scotomas. Invest Ophthalmol Vis Sci 1997;38:1812-8.
37. Crossland MD, Culham LE, Rubin GS. Fixation stability and reading speed in patients with newly developed macular disease. Ophthal Physiol Opt 2004;24:327-33.
38. Fletcher DC, Schuchard RA, Watson G. Relative locations of macular scotomas near the PRL: effect on low vision reading. J Rehabil Res Dev 1999;36:356-64.
39. Cummings RW, Whittaker SG, Watson GR, Budd JM. Scanning characters and reading with a central scotoma. Am J Optom Physiol Opt 1985;62:833-43.
40. Bowers AR, Meek C, Stewart N. Illumination and reading performance in age-related macular degeneration. Clin Exp Optom 2001;84:139-47.
41. Arden GB, Wolf JE. Colour vision testing as an aid to diagnosis and management of age related maculopathy. Br J Ophthalmol 2004;88:1180-5.
42. Holz FG, Gross-Jendroska M, Eckstein A, Hogg CR, Arden GB, Bird AC. Colour contrast sensitivity in patients with age-related Bruch's membrane changes. Ger J Ophthalmol 1995;4:336-41.
43. Falsini B, Fadda A, Iarossi G, Piccardi M, Canu D, Minnella A, Serrao S, Scullica L. Retinal sensitivity to flicker modulation: reduced by early age-related maculopathy. Invest Ophthalmol Vis Sci 2000;41:1498-506.
44. Mayer MJ, Spiegler SJ, Ward B, Glucs A, Kim CB. Preliminary evaluation of flicker sensitivity as a predictive test for exudative age-related maculopathy. Invest Ophthalmol Vis Sci 1992;33:3150-5.
45. Mayer MJ, Ward B, Klein R, Talcott JB, Dougherty RF, Glucs A. Flicker sensitivity and fundus appearance in pre-exudative age-related maculopathy. Invest Ophthalmol Vis Sci 1994;35:1138-49.
46. Phipps JA, Dang TM, Vingrys AJ, Guymer RH. Flicker perimetry losses in age-related macular degeneration. Invest Ophthalmol Vis Sci 2004;45:3355-60.
47. Midena E, Segato T, Blarzino MC, Degli Angeli C. Macular drusen and the sensitivity of the central visual field. Doc Ophthalmol 1994;88:179-85.
48. Eisner A, Fleming SA, Klein ML, Mauldin WM. Sensitivities in older eyes with good acuity: eyes whose fellow eye has exudative AMD. Invest Ophthalmol Vis Sci 1987;28:1832-7.
49. Eisner A, Stoumbos VD, Klein ML, Fleming SA. Relations between fundus appearance and function. Eyes whose fellow eye has exudative age-related macular degeneration. Invest Ophthalmol Vis Sci 1991;32:8-20.
50. Midena E, Degli Angeli C, Blarzino MC, Valenti M, Segato T. Macular function impairment in eyes with early age-related macular degeneration. Invest Ophthalmol Vis Sci 1997;38:469-77.
51. Sunness JS, Massof RW, Johnson MA, Bressler NM, Bressler SB, Fine SL. Diminished foveal sensitivity may predict the development of advanced age-related macular degeneration. Ophthalmology 1989;96:375-81.
52. Phipps JA, Guymer RH, Vingrys AJ. Loss of cone function in age-related maculopathy. Invest Ophthalmol Vis Sci 2003;44:2277-83.
53. Owsley C, Jackson GR, Cideciyan AV, Huang Y, Fine SL, Ho AC, Maguire MG, Lolley V, Jacobson SG. Psychophysical evidence for rod vulnerability in age-related macular degeneration. Invest Ophthalmol Vis Sci 2000;41:267-73.
54. Owsley C, Jackson GR, White M, Feist R, Edwards D. Delays in rod-mediated dark adaptation in early age-related maculopathy. Ophthalmology 2001;108:1196-202.
55. Sandberg MA, Gaudio AR. Slow photostress recovery and disease severity in age-related macular degeneration. Retina 1995;15:407-12.
56. Riusala A, Sarna S, Immonen I. Visual function index (VF-14) in exudative age-related macular degeneration of long duration. Am J Ophthalmol 2003;135:206-12.
57. Hart PM, Chakravarthy U, Stevenson MR, Jamison JQ. A vision specific functional index for use in patients with age related macular degeneration. Br J Ophthalmol 1999;83:1115-20.
58. Clemons TE, Chew EY, Bressler SB, McBee W. National Eye Institute Visual Function Questionnaire in the Age-Related Eye Disease Study (AREDS): AREDS Report No 10. Arch Ophthalmol 2003;121:211-7.
59. Murphy S, Nesbitt P. Advances in management of age-related macular degeneration. Ophthalmic Nursing 2001;5:20-3.
60. Klein R, Peto T, Bird A, Vannewkirk MR. The epidemiology of age-related macular degeneration. Am J Ophthalmol 2004;137:486-95.
61. Lim L, Guymer RH. AMD: to supplement or not? Clin Exp Ophthalmol 2004;32:341-3.
62. Seddon JM, Cote J, Rosner B. Progression of age-related macular degeneration: association with dietary fat, transunsaturated fat, nuts, and fish intake. Arch Ophthalmol 2003;121:1728-37.
63. Seddon JM, Cote J, Davis N, Rosner B. Progression of age-related macular degeneration: association with body mass index, waist circumference, and waist-hip ratio. Arch Ophthalmol 2003;121:785-92.
64. McGwin G Jr, Owsley C, Curcio CA, Crain RJ. The association between statin use and age related maculopathy. Br J Ophthalmol 2003;87:1121-5.
65. Wilson HL, Schwartz DM, Bhatt HR, McCulloch CE, Duncan JL. Statin and aspirin therapy are associated with decreased rates of choroidal neovascularization among patients with age-related macular degeneration. Am J Ophthalmol 2004;137:615-24.
66. Klein R, Klein BE, Tomany SC, Danforth LG, Cruickshanks KJ. Relation of statin use to the 5-year incidence and progression of age-related maculopathy. Arch Ophthalmol 2003;121:1151-5.
67. Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy. Three-year results from randomized clinical trials. Arch Ophthalmol 1986;104:694-701.
68. Macular Photocoagulation Study Group. Krypton laser photocoagulation for neovascular lesions of age-related macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol 1990;108:816-24.
69. Macular Photocoagulation Study Group. Argon laser photocoagulation for senile macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol 1982;100:912-8.
70. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol 1991;109:1220-31.
71. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration. Updated findings from two clinical trials. Arch Ophthalmol 1993;111:1200-9.
72. Fasce F, Brancato R, Bettin P, Introini U, Pece A. Evaluation of fixation one year after perifoveal laser treatment of subfoveal choroidal neovascularization. Int Ophthalmol 1996;20:251-8.
73. Coscas G, Soubrane G, Ramahefasolo C, Fardeau C. Perifoveal laser treatment for subfoveal choroidal new vessels in age-related macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol 1991;109:1258-65.
74. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials - TAP Report 2. Arch Ophthalmol 2001;119:198-207.
75. Verteporfin In Photodynamic Therapy (VIP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - Verteporfin In Photodynamic Therapy Report 2. Am J Ophthalmol 2001;131:541-60.
76. Visudyne in Minimally Classic CNV (VIM) Study Group. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial. Arch Ophthalmol 2005;123:448-57.
77. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) and Verteporfin In Photodynamic Therapy (VIP) Study Groups. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration - TAP and VIP Report No. 1. Am J Ophthalmol 2003;136:407-18.
78. Bunse A, Elsner H, Laqua H, Schmidt-Erfurth U. [Microperimetric documentation of retinal function in photodynamic therapy of choroid neovascularizations.] Klin Monatsbl Augenheilkd 2000;216:158-64.
79. Schmidt-Erfurth UM, Elsner H, Terai N, Benecke A, Dahmen G, Michels SM. Effects of verteporfin therapy on central visual field function. Ophthalmology 2004;111:931-9.
80. Tholen AM, Bernasconi PP, Fierz AB, Messmer EP. [Reading ability after photodynamic therapy (PDT) for age-related macular degeneration (AMD) and for high myopia.] Ophthalmologe 2003;100:28-32.
81. Krebs I, Binder S, Stolba U, Brunner S. Reading ability and central visual field after photodynamic therapy. Ophthalmologica 2004;218:185-92.
82. Kaiser PK, TAP Study Group. Five-year results of verteporfin therapy for subfoveal CNV due to AMD: third year of an open-label extension of the TAP Investigation. Invest Ophthalmol Vis Sci 2003;44:E-abstract 1099.
83. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) and Verteporfin In Photodynamic Therapy (VIP) Study Groups. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: meta-analysis of 2-year safety results in three randomized clinical trials - Treatment Of Age-Related Macular Degeneration With Photodynamic Therapy and Verteporfin In Photodynamic Therapy Study Report no. 4. Retina 2004;24:1-12.
84. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) and Verteporfin In Photodynamic Therapy (VIP) Study Groups. Acute severe visual acuity decrease after photodynamic therapy with verteporfin: case reports from randomized clinical trial - TAP and VIP Report No 3. Am J Ophthalmol 2004;137:683-96.
85. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-16.
86. Eyetech Pharmaceuticals, Inc. Division of Anti-inflammatory, Analgesic and Ophthalmic Drug Products Advisory Committee Meeting Briefing Package for Macugen. 2004. Available at: www. fda.gov/ohrms/dockets/ac/04/briefing/2004- 4053B1_02_FDA-Backgrounder.pdf. Accessed November 14, 2005.
87. Eyetech Pharmaceuticals, Inc. Corrections for Macugen Briefing Document (NDA 21-756). 2004. Available at: www.fda.gov/ ohrms/dockets/ac/04/briefing/ 2004-4053B1_03_FDA-Backgrounder-Errata.pdf. Accessed November 14, 2005.
88. D'Amico DJ, VISION Clinical Trial Group. VEGF Inhibition Study in Ocular Neovascularization (VISION): second year efficacy data. Invest Ophthalmol Vis Sci 2005;46:E-abstract 2309.
89. Eyetech Pharmaceuticals, Inc. Macugen® (pegaptanib sodium) prescribing information. 2005. Available at: www.macugen.com/ macugen_PI.pdf. Accessed November 14, 2005.
90. Mieler W, VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group. Safety evaluation of second year treatment of age-related macular degeneration with pegaptanib sodium (Macugen™): VEGF Inhibition Study In Ocular Neovascularization (VISION). Invest Ophthalmol Vis Sci 2005;46:E-abstract 1380.
91. Frennesson C, Jakobsson P, Nilsson UL. A computer and video display based system for training eccentric viewing in macular degeneration with an absolute central scotoma. Doc Ophthalmol 1995;91:9-16.
92. Nilsson UL, Frennesson C, Nilsson SE. Patients with AMD and a large absolute central scotoma can be trained successfully to use eccentric viewing, as demonstrated in a scanning laser ophthalmoscope. Vision Res 2003;43:1777-87.
93. Schuchard RA, Naseer S, de Castro K. Characteristics of AMD patients with low vision receiving visual rehabilitation. J Rehabil Res Dev 1999;36:294-302.
94. Fletcher DC, Schuchard RA, Livingstone CL, Crane WG, Hu SY. Scanning laser ophthalmoscope macular perimetry and applications for low vision rehabilitation. Ophthalmol Clin North Am 1994;7:257-65.
95. Brody BL, Williams RA, Thomas RG, Kaplan RM, Chu RM, Brown SI. Age-related macular degeneration: a randomized clinical trial of a self-management intervention. Ann Behav Med 1999;21:322-9.
96. Owen J, Herse P. Low vision and surfing. Optom Vis Sci 1996;73:558-61.
97. Rubin GS. Vision rehabilitation for patients with age-related macular degeneration. Eye 2001;15:430-5.
98. Wolffsohn JS, Dinardo C, Vingrys AJ. Benefit of coloured lenses for age-related macular degeneration. Ophthal Physiol Opt 2002;22: 300-11.
99. Wolffsohn JS, Cochrane AL, Khoo H, Yoshimitsu Y, Wu S. Contrast is enhanced by yellow lenses because of selective reduction of short-wavelength light. Optom Vis Sci 2000;77:73-81.
100. Eperjesi F, Fowler CW, Evans BJ. Effect of light filters on reading speed in normal and low vision due to age-related macular degeneration. Ophthal Physiol Opt 2004;24:17-25.